Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy ...Middle East

Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission. In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and...

Read More Details
Finally We wish PressBee provided you with enough information of ( Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy )

Also on site :

• Nazi symbols prevalent in Ukrainian military – Le Monde
• Kremlin comments on possible US strike on Iran
• Israel threatens to kill Iran’s supreme leader after missile strikes